Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07300709

Renal Histopathology and Transcriptomic Analysis in Hepatorenal Syndrome During Liver Transplantation

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
42 (estimated)
Sponsor
The University of Hong Kong · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hepatorenal Syndrome (HRS) is a serious complication that can occur in patients with liver cirrhosis, characterised by kidney dysfunction, or acute kidney failure (AKI). While it has traditionally been thought that HRS affects structurally normal kidneys and is completely reversible with liver transplantation, recent evidence suggests this may not always be the case. The purpose of this study is to examine the actual structural changes in the kidneys of patients with HRS through tissue biopsy and advanced molecular analysis. This may help us better understand the disease mechanism and potentially improve treatment approaches. We aim to challenge the current understanding that HRS always occurs in structurally normal kidneys and is always reversible after liver transplantation. This study will provide valuable insights into the pathophysiology of HRS and may lead to improved diagnostic and treatment strategies in the future. This is a 3-year single center prospective, non-randomised, open label study at Queen Mary Hospital, The University of Hong Kong. All consecutive patients accepted on the liver transplant waiting list will be invited to participate. Patient will undergo several procedures related to liver transplant and kidney assessment, and receive liver transplantation and renal biopsy.

Conditions

Interventions

TypeNameDescription
PROCEDURErenal biopsyTo examine the actual structural changes in kidneys of patients with HRS through tissue biopsy and advanced molecular analysis, and hope that may help us better understand the disease mechanism and potentially improve treatment approaches

Timeline

Start date
2026-01-01
Primary completion
2028-08-01
Completion
2028-12-01
First posted
2025-12-24
Last updated
2025-12-24

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT07300709. Inclusion in this directory is not an endorsement.